JonesTrading has begun coverage on shares of Evaxion A/S (NASDAQ: EVAX), offering a positive outlook in a research report published on March 5, 2024. The firm has issued a “buy” rating along with a price target of $10.00 for the stock, indicating confidence in the company’s potential growth.
Several other analysts have recently provided their assessments of Evaxion A/S. Lake Street Capital adjusted its price target from $11.00 to $9.00 while maintaining a “buy” rating. In a separate report, Maxim Group also initiated coverage, setting a “buy” rating and a price objective of $10.00. Meanwhile, HC Wainwright reaffirmed a “buy” rating, with a target price of $16.00. However, Weiss Ratings provided a contrasting viewpoint, restating a “sell (d-)” rating on January 9, 2024.
Currently, five research analysts rate Evaxion A/S as a “buy,” while one has issued a “sell” rating. According to MarketBeat.com, the stock holds an average rating of “Moderate Buy” and an average price target of $11.00.
Recent Financial Performance
Evaxion A/S reported its quarterly earnings on March 5, 2024, revealing an earnings per share (EPS) of $0.30 for the quarter. Analysts collectively anticipate a projected EPS of -0.15 for the current financial year, reflecting the challenges faced by the clinical-stage biotechnology firm as it advances its product pipeline.
In terms of institutional investment, recent shifts have occurred. Wesbanco Bank Inc. acquired a new stake in Evaxion A/S during the fourth quarter, valued at $48,000. Similarly, Northwestern Mutual Wealth Management Co. purchased shares worth $38,000, and SmartHarvest Portfolios LLC invested $72,000 in the same period. Institutional investors now hold approximately 11.04% of the company’s stock.
About Evaxion A/S
Headquartered in Copenhagen, Denmark, with additional operations in the United States, Evaxion A/S specializes in developing immunotherapies and vaccines. The company utilizes a proprietary AI-based computational immunology platform to optimize antigen targets for therapeutic cancer vaccines and vaccines against infectious diseases. By employing machine learning and deep learning algorithms, Evaxion analyzes vast datasets of genomic, proteomic, and immunological information to predict immune-stimulating epitopes, positioning itself as a pioneer in the biotech industry.
As the company moves forward, its ability to navigate market responses and enhance its product offerings will be crucial. The diverse views from analysts reflect a dynamic landscape around Evaxion A/S, highlighting both potential and caution as the firm continues its journey in the biotechnology sector.
